Axa S.A. Neurocrine Biosciences Inc Transaction History

Axa S.A.

$32.3 Billion
Q3 2024

A detailed history of Axa S.A. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Axa S.A. holds 269,172 shares of NBIX stock, worth $39.5 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

269,172

Previous 284,022 5.23%

Holding current value

$39.5 Million

Previous $39.1 Million 20.75%

% of portfolio

0.1%

Previous 0.12%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $1.7 Million - $2.27 Million	-14,850 Reduced 5.23%	269,172 $31 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $5.28 Million - $5.78 Million	40,333 Added 16.55%	284,022 $39.1 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $16.6 Million - $18.3 Million	127,478 Added 109.7%	243,689 $33.6 Million
Q4 2023 Jul 16, 2024	SELL	$106.07 - $132.76 $13.5 Million - $16.9 Million	-127,478 Reduced 52.31%	116,211 $15.3 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $288,298 - $360,841	-2,718 Reduced 2.29%	116,211 $15.3 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $2.98 Million - $3.71 Million	31,664 Added 36.28%	118,929 $13.4 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $3.19 Million - $3.73 Million	35,604 Added 68.92%	87,265 $8.23 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $1.8 Million - $2.36 Million	-19,158 Reduced 27.05%	51,661 $5.23 Million
Q4 2022 Feb 14, 2023	SELL	$106.72 - $127.06 $2.19 Million - $2.61 Million	-20,504 Reduced 22.45%	70,819 $8.46 Million
Q3 2022 Feb 14, 2023	SELL	$92.03 - $107.81 $1.56 Million - $1.83 Million	-16,947 Reduced 15.65%	91,323 $9.7 Million
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $1.56 Million - $1.83 Million	-16,947 Reduced 15.65%	91,323 $9.7 Million
Q2 2022 Feb 14, 2023	BUY	$75.79 - $100.07 $3.76 Million - $4.96 Million	49,602 Added 84.55%	108,270 $10.6 Million
Q2 2022 Aug 15, 2022	BUY	$75.79 - $100.07 $3.76 Million - $4.96 Million	49,602 Added 84.55%	108,270 $10.6 Million
Q1 2022 Feb 14, 2023	SELL	$72.45 - $94.81 $2.37 Million - $3.1 Million	-32,655 Reduced 35.76%	58,668 $5.5 Million
Q1 2022 May 13, 2022	BUY	$72.45 - $94.81 $4.25 Million - $5.56 Million	58,668 New	58,668 $5.5 Million
Q4 2021 Feb 14, 2022	SELL	$79.65 - $106.22 $493,830 - $658,564	-6,200 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$89.43 - $102.27 $368,898 - $421,863	4,125 Added 198.8%	6,200 $603,000
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $1.21 Million - $1.64 Million	-13,766 Reduced 86.9%	2,075 $202,000
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $4.71 Million - $5.87 Million	-54,215 Reduced 77.39%	15,841 $1.52 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $1.95 Million - $2.74 Million	-20,255 Reduced 22.43%	70,056 $6.74 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $860,344 - $1.32 Million	10,111 Added 12.61%	90,311 $11 Million
Q1 2020 May 15, 2020	BUY	$75.11 - $113.76 $458,771 - $694,846	6,108 Added 8.24%	80,200 $6.94 Million
Q4 2019 Feb 18, 2020	BUY	$86.8 - $118.57 $6.43 Million - $8.79 Million	74,092 New	74,092 $7.96 Million
Q4 2018 Feb 13, 2019	SELL	$68.32 - $124.36 $4.7 Million - $8.56 Million	-68,822 Closed	0 $0
Q3 2018 Nov 08, 2018	SELL	$98.88 - $125.85 $1.46 Million - $1.85 Million	-14,730 Reduced 17.63%	68,822 $8.46 Million
Q2 2018 Aug 13, 2018	BUY	$75.3 - $105.99 $80,043 - $112,667	1,063 Added 1.29%	83,552 $8.21 Million
Q1 2018 May 14, 2018	SELL	$75.88 - $92.43 $4.95 Million - $6.03 Million	-65,221 Reduced 44.15%	82,489 $6.84 Million
Q4 2017 Feb 13, 2018	SELL	$58.53 - $77.59 $8,662 - $11,483	-148 Reduced 0.1%	147,710 $11.5 Million
Q3 2017 Nov 13, 2017	BUY	$47.97 - $61.28 $7.09 Million - $9.06 Million	147,858	147,858 $9.06 Million

Others Institutions Holding NBIX

# of Institutions

631

Shares Held

93.9M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $14B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account